title: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
abstract: Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) by ipilimumab leads to immune-mediated tumor regression and immune-related adverse events (irAEs), including diarrhea and colitis. The current analyses were undertaken to promote an understanding of the underlying mechanism of action and to identify potential biomarkers that could help in the prediction and management of ipilimumab-induced gastrointestinal irAEs. Treatment-naïve or previously treated patients with unresectable stage III/IV melanoma (n = 115) received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) and were randomized to receive concomitant blinded prophylactic oral budesonide (9 mg/d with gradual taper through week 16) or placebo. Outcome measures included histologic assessment of bowel biopsies and assessment of serologic markers of inflammatory bowel disease (IBD), fecal calprotectin levels, and polymorphisms in immune-related genes. Ipilimumab resulted in dysregulation of gastrointestinal mucosal immunity as evidenced by altered antibody levels to enteric flora, inflammatory cell infiltration into gastrointestinal mucosa, and increased fecal calprotectin associated with diarrhea and clinical evidence of colitis. The pattern of ipilimumab-induced antibody titers to microbial flora and the histologic features and location of the inflammation were distinct from classic IBD. Prophylactic budesonide did not prevent ipilimumab-induced bowel inflammation. Despite an observed association between colonic inflammation and grade 2 or higher diarrhea, no baseline biomarkers could reliably predict development of gastrointestinal toxicity. Although classic IBD and ipilimumab-related gastrointestinal toxicity are both immune mediated, the observed pattern of biomarkers suggests ipilimumab-related gastrointestinal toxicity may be a distinct clinicopathologic entity.
authors.affiliation: Bristol-Myers Squibb Company, Princeton, New Jersey, USA. david.berman@bms.com
authors.forename: David
authors.initials: D
authors.lastname: Berman
authors.forename: Susan M
authors.initials: SM
authors.lastname: Parker
authors.forename: Jonathan
authors.initials: J
authors.lastname: Siegel
authors.forename: Scott D
authors.initials: SD
authors.lastname: Chasalow
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Weber
authors.forename: Susan
authors.initials: S
authors.lastname: Galbraith
authors.forename: Stephan R
authors.initials: SR
authors.lastname: Targan
authors.forename: Hanlin L
authors.initials: HL
authors.lastname: Wang
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology*; D019819:Budesonide / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D003092:Colitis / Q000139:chemically induced / Q000276:immunology; D003967:Diarrhea / Q000139:chemically induced / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D019819:Budesonide